ProKidney Reports Q3 2026 Results, $141.9 Million in Cash and PROACT 1 Progress

ProKidney reported a third-quarter 2026 net loss before noncontrolling interest of $51.8 million, compared with $35.8 million a year earlier. The company ended September with $141.9 million in cash, cash equivalents and marketable securities. It remains on track to report pivotal PROACT 1 eGFR slop…